{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=talazoparib",
    "query": {
      "intervention": "talazoparib"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=talazoparib&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T22:45:31.634Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01286987",
      "title": "Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Recurrent Solid Tumors",
        "Breast Neoplasms",
        "Ovarian Cancer, Epithelial",
        "Ewing Sarcoma",
        "Small Cell Lung Carcinoma",
        "Prostate Cancer",
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2011-01-03",
      "completion_date": "2017-01-30",
      "has_results": true,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01286987"
    },
    {
      "nct_id": "NCT04987931",
      "title": "Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2021-08-20",
      "completion_date": "2021-10-11",
      "has_results": true,
      "last_update_posted_date": "2024-01-22",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04987931"
    },
    {
      "nct_id": "NCT02049593",
      "title": "PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Unspecified Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "PARP inhibitor BMN-673",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2014-06-12",
      "completion_date": "2019-10-07",
      "has_results": false,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02049593"
    },
    {
      "nct_id": "NCT02921919",
      "title": "Open-Label Extension and Safety Study of Talazoparib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2016-11-08",
      "completion_date": "2021-07-20",
      "has_results": true,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 26,
      "location_summary": "Alhambra, California • Bakersfield, California • Burbank, California + 16 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02921919"
    },
    {
      "nct_id": "NCT03499353",
      "title": "Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TALAZOPARIB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2018-08-27",
      "completion_date": "2020-09-23",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 97,
      "location_summary": "Gilbert, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 64 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Camarillo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03499353"
    },
    {
      "nct_id": "NCT04550494",
      "title": "Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Castration-Resistant Prostate Carcinoma",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "HER2-Positive Breast Carcinoma",
        "Locally Advanced Breast Carcinoma",
        "Locally Advanced Gastric Carcinoma",
        "Locally Advanced Malignant Solid Neoplasm",
        "Locally Advanced Ovarian Carcinoma",
        "Locally Advanced Pancreatic Carcinoma",
        "Locally Advanced Prostate Carcinoma",
        "Metastatic Breast Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Pancreatic Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Platinum-Sensitive Ovarian Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Gastric Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Stage IV Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2021-04-26",
      "completion_date": "2027-07-27",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 4,
      "location_summary": "Gainesville, Florida • Bethesda, Maryland • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04550494"
    },
    {
      "nct_id": "NCT04849364",
      "title": "Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Inavolisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bryan Schneider, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2021-08-24",
      "completion_date": "2024-12-02",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Hollywood, Florida + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04849364"
    },
    {
      "nct_id": "NCT03968406",
      "title": "Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Female Reproductive System Neoplasm",
        "Recurrent Cervical Carcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Vaginal Carcinoma",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVA Vaginal Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Stage IVB Vaginal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-09-26",
      "completion_date": "2027-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03968406"
    },
    {
      "nct_id": "NCT01989546",
      "title": "Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Advanced Breast Cancer",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BMN 673",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 9,
      "start_date": "2014-02-04",
      "completion_date": "2020-03-26",
      "has_results": true,
      "last_update_posted_date": "2021-02-23",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01989546"
    },
    {
      "nct_id": "NCT02997176",
      "title": "An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2016-09-30",
      "completion_date": "2020-02-12",
      "has_results": true,
      "last_update_posted_date": "2021-02-25",
      "last_synced_at": "2026-09-02T22:45:31.634Z",
      "location_count": 11,
      "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 7 more",
      "locations": [
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02997176"
    }
  ]
}